Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03785288 · ClinicalTrials.gov registry record · Phase 3
Vaginal Cuff Brachytherapy Fractionation Study
A Phase 3 study of Endometrial Cancer, sponsored by Kara Romano, MD.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 258
- Enrollment target
- 3
- Study locations
NCT03785288: Recruiting Phase 3 study of Endometrial Cancer, sponsored by Kara Romano, MD.
NCT03785288 is a Phase 3 study of Endometrial Cancer that is actively recruiting participants, run by Kara Romano, MD. The registered enrollment target is 258 participants, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (51% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03785288, a Phase 3 study of Endometrial Cancer, is actively recruiting participants, sponsored by Kara Romano, MD.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 258 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to see the effects of two different standard of care treatments of endometrial cancer on sexual dysfunction. This study will compare two standard of care treatments: HDR (high dose radiation) vaginal brachytherapy 3 fractions of 7 Gy to HDR vaginal brachytherapy 6 fractions of 4Gy for early stage endometrial cancer.
Primary Outcome
Using the FSFI, compare patient reported sexual dysfunction at 1 year after completion of treatment
Conditions Studied
Interventions
- RADIATION HDR vaginal brachytherapy
Study Locations (3)
Maryland
- University of Maryland Medical Center (UMMC) - Baltimore
New York
- SUNY Upstate Medical University - Syracuse
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 258 participants |
| Start Date | 2019-01-17 |
| Est. Completion | 2026-01-01 |
| Phase | Phase 3 |
What NCT03785288 shows while recruiting
NCT03785288 is an interventional study that assigns participants to a tested intervention. The registered 258 participants enrollment target is mid-sized for trials with a published cap, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 1 intervention - of which HDR vaginal brachytherapy is the first listed.
NCT03785288 reports a single indexed study location in Maryland, New York, Virginia.
Frequently Asked Questions
What is clinical trial NCT03785288 about?
NCT03785288 is a clinical study titled "Vaginal Cuff Brachytherapy Fractionation Study". The purpose of this study is to see the effects of two different standard of care treatments of endometrial cancer on sexual dysfunction. This study will compare two standard of care treatments: HDR (high dose radiation) vaginal brachytherapy 3 fractions of 7 Gy to HDR vaginal brachytherapy 6 fracti...
What is the current status of trial NCT03785288?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 258 participants. The study started on 2019-01-17. Estimated completion is 2026-01-01.
What conditions does trial NCT03785288 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT03785288?
The interventions under investigation include: HDR vaginal brachytherapy (RADIATION).
Who is sponsoring clinical trial NCT03785288?
This trial is sponsored by Kara Romano, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03785288 being conducted?
This trial has 3 study locations across Maryland, New York, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03785288's enrollment target sits among peer trials
258 56th of 181 higher than 125 of 181 other Endometrial Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RECRUITING · Phase 3
-
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
RECRUITING · Phase 3
-
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RECRUITING · Phase 3
-
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
RECRUITING · Phase 3
-
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04643002 · 258 participants · Phase 1
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
- NCT04924322 · 258 participants · Phase 2
Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies
- NCT05043012 · 258 participants · NA
Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study)
- NCT05482893 · 258 participants · Phase 1
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI